Genetic Signatures Limited (ASX:GSS)

Australia flag Australia · Delayed Price · Currency is AUD
0.0950
-0.0050 (-5.00%)
At close: Mar 6, 2026
-82.08%
Market Cap 21.58M
Revenue (ttm) 19.94M
Net Income (ttm) -11.27M
Shares Out 227.14M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 375,599
Average Volume 249,335
Open 0.1000
Previous Close 0.1000
Day's Range 0.0950 - 0.1000
52-Week Range 0.0950 - 0.6900
Beta 0.44
RSI 27.18
Earnings Date Feb 26, 2026

About Genetic Signatures

Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. The company was incorporated in 2001 and is headquartered in Newtown, Australia. [Read more]

Sector Healthcare
Founded 2001
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol GSS
Full Company Profile

Financial Performance

In fiscal year 2025, Genetic Signatures's revenue was 19.75 million, an increase of 43.47% compared to the previous year's 13.77 million. Losses were -20.10 million, 12.6% more than in 2024.

Financial Statements

News

There is no news available yet.